Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial.

Saved in:
Bibliographic Details
Title: Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial.
Authors: Hensley M; Hensley Biostats, Seattle, WA, United States., Lengfeld J; Martell Diagnostic Laboratories, Roseville, MN, United States., Stoesz S; Martell Diagnostic Laboratories, Roseville, MN, United States., Edwards M; Martell Diagnostic Laboratories, Roseville, MN, United States., Pass F; Martell Diagnostic Laboratories, Roseville, MN, United States., Hirst GL; Department of Surgery, University of California, San Francisco, San Francisco, CA, United States., Brown-Swigart L; Department of Surgery, University of California, San Francisco, San Francisco, CA, United States., van 't Veer L; Department of Surgery, University of California, San Francisco, San Francisco, CA, United States., Esserman LJ; Department of Surgery, University of California, San Francisco, San Francisco, CA, United States., Beckwith H; Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN, United States., Yee D; Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN, United States.; Masonic Cancer Center, University of Minnesota, Minneapolis, MN, United States.
Source: Frontiers in oncology [Front Oncol] 2025 Jul 24; Vol. 15, pp. 1605120. Date of Electronic Publication: 2025 Jul 24 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2234-943X
DOI:10.3389/fonc.2025.1605120